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Natural killer (NK) cells are major effectors of the innate immune response. Despite an 
overall defect in their function associated with chronic human immunodeficiency virus 
(HIV) infection, their role in primary HIV infection is poorly understood. We investigated 
the modifications of the NK cell compartment in patients from the ANRS-147-Optiprim 
trial, a study designed to examine the benefits of intensive combination antiretroviral 
therapy (cART) in patients with acute or early primary HIV infection. Multiparametric flow 
cytometry combined with bioinformatics analyses identified the NK phenotypes in blood 
samples from 30 primary HIV-infected patients collected at inclusion and after 3 months of 
cART. NK phenotypes were revealed by co-expression of CD56/CD16/NKG2A/NKG2C 
and CD57, five markers known to delineate stages of NK maturation. Three groups 
of patients were formed according to their distributions of the 12 NK cell phenotypes 
identified. Their virological and immunological characteristics were compared along with 
the early outcome of cART. At inclusion, HIV-infected individuals could be grouped into 
those with predominantly immature/early differentiated NK cells and those with predom-
inantly mature NK cells. Several virological and immunological markers were improved in 
patients with mature NK profiles, including lower HIV viral loads, lower immune activation 
markers on NK and dendritic cell (DC), lower levels of plasma IL-6 and IP-10, and a trend 
to normal DC counts. Whereas all patients showed a decrease of viremia higher than 3 
log10 copies/ml after 3 months of treatment, patients with a mature NK profile at inclusion 
Abbreviations: PBMCs, peripheral blood mononuclear cells; NK cell, natural killer cell; PTC, posttreatment controller; KIR, 
killer-cell immunoglobulin-like receptor; HIV, human immunodeficiency virus; PMT, photo-multiplicators.
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inTrODUcTiOn
Natural killer (NK) cells are one of the major innate immune 
components involved in the rapid response of the host to invading 
virus (1). Their function is probably crucial at the time of infec-
tion and can impact the quality of adaptive immune responses 
and the overall outcome of infections. NK cell activity is regulated 
by activating and inhibitory receptors, but their effector functions 
are intrinsically linked to their maturation (2). Cytolysis is the 
typical NK cell function, but NK cell also play an antiviral role 
through the release of soluble factors, such as IFN-γ and TNF-α  
(3), which activate T cells, macrophages, and dendritic cells 
(DCs). CD56bright NK cells are described as the progenitors of 
CD56dim, the latter being endowed with the main NK cell effec-
tor functions (2). CD56dim cells sequentially progress from an 
immature population, characterized by a high degranulation and 
proliferation potential, to a terminally differentiated population, 
characterized by potent cytokine production at the expense of 
cell division and degranulation (4). Immature NK cells express 
NKG2A, a C-type lectin receptor forming an inhibitory heterodi-
mer with CD94 to interact with HLA-E on target cells (5). HLA-E 
is a non-classical major histocompatibility complex (MHC) 
class I molecule whose expression is enhanced on infected cells 
through the presentation of viral peptides (6). During maturation, 
NKG2A loss is compensated by the acquisition of self-inhibitory 
killer-cell immunoglobulin-like receptor (KIR) expression, while 
CD57, a marker of senescence, is acquired (4). NKG2C/CD94 is 
the activating alternative receptor of HLA-E on NK cells (7). This 
receptor was initially described on a subset of NK cells expanded 
during CMV infection (8, 9), but recently, other viruses, including 
human immunodeficiency virus (HIV), were also shown to drive 
NKG2C+ NK cell expansion, in the context of CMV co-infection 
(10, 11). The persistence of a NKG2C+CD57+ NK cell subset for 
more than 1 year after CMV or Hantavirus infection has led to 
the proposition that they are a memory-like form of NK cell (8, 
12, 13). Therefore, the co-expression of CD56, CD16, NKG2A, 
NKG2C, and CD57 delineates sequential stages of the NK cell 
maturation process suggesting the acquisition of typical effector 
functions.
Natural killer cell functions are affected early after HIV 
infection (14). In addition, many modifications of the NK 
cell compartment, including decrease of CD56bright, expansion 
of CD56dim, and appearance of a functionally compromised 
subset of CD56dim expressing low levels of CD56 or CD16 were 
reported (15). Inversion of the ratio of NKG2A to NKG2C was 
described in primary HIV-infected patients (11, 16). In chroni-
cally infected patients, an overall increase of mature CD57+ NK 
cells was observed (17). In cohort of individualist risk of HIV 
infection, NK cell activation at the time of primary infection 
has been both positively and negatively correlated with the 
risk of HIV acquisition (18, 19). Recently, a correlation was 
demonstrated between NK cell repertoire diversity, linked to 
progression to maturity, and increased susceptibility to HIV 
infection (20). Therefore, while NK maturation seems to be an 
interesting parameter in HIV infection, so far, the impact of the 
overall maturation of NK cells on the outcome of primary HIV-
infection (PHI) remains elusive.
The Optiprim trial was designed to evaluate to what extent 
intensive antiviral therapy started during primary HIV infection 
contributes to a decrease in the size of HIV reservoirs and helps 
to achieve a so-called posttreatment controller (PTC) status (21). 
A sub-study was designed to investigate innate immune param-
eters. Considering the important role of NK cell maturation for 
their effector properties, we investigated the NK cell compart-
ment with a combination of markers known to characterize 
sequential steps of the NK cell differentiation pathway. Thirty 
primary HIV-infected patients peripheral blood mononuclear 
cell (PBMC) samples were investigated at inclusion and 3 months 
after the onset of combination antiretroviral therapy (cART). 
Because cell populations expressing unexpected combinations 
of markers might be expanded in pathological conditions, new 
bioinformatics methods were applied to analyze multiparametric 
cytometry data in an unsupervised approach (22). This allowed 
the identification of a relationship between profiles of NK cells 
skewed to immaturity or maturity and virological and immune 
parameters reached naturally a few weeks after infection and after 
early cART.
sUBJecTs anD MeThODs
ethical statement
All study participants provided written informed consent.
The study was approved by the Sud-Mediterranee-1 Ethics 
Committee and the French Health Products Safety Agency and 
complied with the Helsinki Declaration.
reached this threshold more rapidly than patients with an immature NK profile (70 vs. 
38%). In conclusion, a better early response to cART is observed in patients whose NK 
profile is skewed to maturation at inclusion. Whether the mature NK cells contributed 
directly or indirectly to HIV control through a better immune environment under cART is 
unknown. The NK maturation status of primary infected patients should be considered 
as a relevant marker of an immune process contributing to the early outcome of cART 
that could help in the management of HIV-infected patients.
Keywords: hiV, primary infection, nK cells maturation, carT, memory-like nK
TaBle 1 | Patients’ characteristics at inclusion.
Number of patients 30
Number of patients acutely infected 14
Time between estimated date of infection and enrollment 
(days)
34 (20–55)
Age (years) 39.4 (23–55)
Number of patients handled by intensive combination 
antiretroviral therapy
15
CD4 counts at T0 (count/μL) 550 (323–1,012)
CD8 counts at T0 (count/μL) 1,704 (417–8,157)
CD4 to CD8 ratio at T0 0.47 (0.08–1.32)
Human immunodeficiency virus (HIV)-RNA at T0 
(log10 copies/mL)
5.51 (3.2–7)
HIV-DNA at T0 [log10 copies/106 peripheral blood 
mononuclear cell (PBMC)]
3.747 (2.78–4.68)
CD4 counts at M3 (count/μL) 656 (275–1,244)
CD8 counts at M3 (count/μL) 705 (371–1,282)
HIV-RNA at M3 (log10 copies/mL) 1.88 (1.3–3.42)
HIV-DNA at M3 (log10 copies/106 PBMC) 2.93 (2.25–3.62)
Mean values and (range) are indicated.
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study Population
Human immunodeficiency virus-1-infected subjects with 
PHI were included in a multicenter phase 3 randomized trial 
(ANRS-147 OPTIPRIM) (www.ClinicalTrials.gov, number 
NCT01033760). The endpoint was the impact of intensive vs. 
standard cART at month 24 on blood HIV-DNA levels. The 
results of this study have been published (21). Antoine Chéret was 
the Principal Investigator, Laurence Meyer the Methodological 
Investigator, and Christine Rouzioux the Virologist Investigator. 
We proposed a sub-study where the participants would give blood 
samples at day 0 (before cART initiation) and month 3. This sub-
study, in which Daniel Olive and Françoise Gondois-Rey were 
the investigators, was designed to investigate parameters of innate 
immunity linked to cART efficacy. Among 90 patients in the main 
study, 30 patients were randomly included in this sub-study. This 
work shows original data on NK cells, DC, CMV, and plasma 
cytokines, and uses information from the main study. Patient 
characteristics are listed in Table 1.
Fifteen healthy donor samples were obtained from the French 
Blood Bank (EFS, Etablissement Français du Sang) as controls. 
PBMC samples were frozen and kept in liquid nitrogen until 
tested.
Flow cytometry
Peripheral blood mononuclear cells were stained with multipara-
metric panels containing 9 or 12 fluorescent markers, respectively, 
designed to investigate NK and DC populations. The NK panel 
contained NKG2A-PacBlue (clone Z199, home-made), live–dead 
Aqua (Life Technology), CD57-FITC (Beckman Coulter; 1/30), 
NKG2C-PE (R&D; 1/40), CD14-PC5 (Beckman Coulter; 1/30), 
CD19-PC5 (Beckman Coulter; 1/30), CD56-PC7 (Beckman 
Coulter; 1/30), CD3-AF700 (BD Biosciences; 1/40), and CD16-
APCH7 (BD Biosciences; 1/40). The DC panel contained live–
dead Aqua (Life Technology), BDCA2-FITC (Miltényi; 1/30), 
CD123-PercpCy5.5 (BD Biosciences; 1/20), HLA-DR-ECD 
(Beckmann Coulter; 1/40), CD3-PC5 (BD Biosciences; 1/40), 
CD56-PC5 (Beckman Coulter; 1/30), CD19-PC5 (Beckman 
Coulter; 1/40), CD33-PC7 (BD Biosciences; 1/40), CD14-APCH7 
(BD biosciences; 1/40), and CD16-AF700 (BD Biosciences; 
1/40). Cells were incubated for 20 min at RT with reagents pre-
mixed in PBS, washed, and then fixed with 4% PFA. Data were 
acquired on a LSRII-SORP (BD Biosciences) equipped with four 
lasers (405 nm/100 mW, 488 nm/100 mW, 560 nm/50 mW, and 
630 nm/40 mW). Photo-multiplicators were set using unstained 
and fully stained samples and linked to the cytometer standardiza-
tion using the acquisition setting tool. Also, 7.74 × 106 ± 3 × 105 
events were recorded. Compensations were performed with 
beads individually stained with corresponding reagents.
Flow cytometry Data analysis
Data were exported and analyzed with FlowJo (version 9-2, 
MacOS X). NK cells were gated as CD3−CD14−CD19−CD56+ 
CD16+, CD3−CD14−CD19−CD56+CD16−, or CD3−CD14−CD19− 
CD56−CD16+ (Figure S1 in Supplementary Material). 
Contaminating non-classical monocytes represented less than 
0.11% of the gated events (not shown). The remaining data 
(3.5 × 105 ± 2.5 × 104 events) were exported to create new files 
further subjected to automated gating. DC’s were defined as 
CD3−CD14−CD19−CD56−CD16−HLA-DR+live cells. In the DC 
gate, the pDC were gated as CD33lowBDCA2+CD123+ cells, the 
mDC as CD33highBDCA2−CD123− cells.
automatic clustering
The flowClust implementation version 3.4.11on R version 3.1.2 
under Linux Cent OS 6 was applied on the following param-
eters: CD56-PC7, CD16-APCH7, NKG2A-PacBlue, NKG2C-PE, 
CD57-FITC, to compute clusters as described (22). The number 
of clusters that fit the data optimally was estimated by computing 
flowClust on a predefined range and comparing them with the 
statistical criteria BIC and ICL (not shown). This number was 
estimated to be above 20; therefore, 27 clusters were computed 
in the events within the NK gate of the 60 samples (30 patients, 
T0, and M3) and one healthy donor. Two samples failed to be 
computed.
MFI values and event counts of the 1,593 clusters generated 
after computation were exported in an Excel table.
Multiparametric Data Management  
with MeV
MeV (version 4.9.0, https://sourceforge.net/projects/mev-tm4/) 
(23) was used to visualize and group multiparametric clusters 
using hierarchical clustering (HCL) of their centers of CD56, 
CD16, CD57, NKG2A, and NKG2C MFI. Euclidean distance 
and average linkage were chosen. Prior to MeV, centers were 
rescaled to adjust the 5 (respectively, 95) percentile of each 
dimension to −3 (respectively, +3) and normalized. The tree 
was cut interactively using objective MeV tools and color inter-
pretation of the heatmap to define populations as homogeneous 
groups of clusters. Names were interactively given according to 
the comparisons of signatures between groups and the expres-
sion of known NK cell markers. The blocks were saved and 
imported in a spreadsheet program, leading to a matrix with 
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a population identifier column associated to the initial count 
of events. The percentages of each population of each patient 
sample were summarized using pivot tables.
Virus Quantification
Human immunodeficiency virus-RNA was quantified in plasma 
by real-time RT-PCR with the Cobas TaqMan HIV1 v2.0 assay 
(Roche Diagnostics). Threshold values were arbitrarily given to 
samples below the threshold of the assay (20 RNA copies/mL). 
Total HIV-DNA was quantified by ultra-sensitive real-time PCR 
in PBMC using the Generic HIV-DNA assay from BioCentric 
(Bandol, France) as described (24).
cytokine Quantification
Plasma Cytokines
IP-10 concentrations were determined in stored plasma or serum 
samples (−80°C) by specific enzyme-linked immunosorbent 
assay, human Quantikine CXCL10 (R&D Systems, Minneapolis, 
MN, USA) according to the manufacturers’ instructions. Levels of 
IL-6 were measured in frozen plasma samples with specific ELISA 
assays (Human IL-6 Platinum ELISA, eBioscience). Samples with 
undetectable levels of IL-6 were arbitrarily attributed half the 
minimal detectable value (0.46 pg/mL).
statistics
Statistical graphics were performed with Prism 6 software. The 
Kruskall–Wallis test followed by multiple comparison Dunn’s 
posttest were used to compare variables between groups. 
Correlations were evaluated by using simple linear regression 
analysis and Spearman’s rank correlation test.
resUlTs
automatic clustering revealed nK cell 
Differentiation subtypes within hiV-
Primary infected Patients’ PBMcs
We investigated the phenotypes of differentiation of NK cells 
with multiparametric cytometry using CD56, CD16, NKG2A, 
CD57, and NKG2C, known to delineate sequential stages of 
NK cell maturation (2, 4). In order to discover unexpected 
populations, multi-stained samples were analyzed through 
unsupervised computation of clusters, using a method previ-
ously validated (22). Computed clusters were visualized in a 
MeV heatmap according to their normalized MFI for the five 
markers and merged to identify populations as homogeneous 
groups of clusters (Figure 1). The tree was interactively cut to 
summarize the results in 19 groups, using objective tools of 
MeV and a subjective overview of the heatmap (Figure 1). Six 
of them including only a few clusters were excluded because 
of their rare representation. Thirteen groups were named 
according to comparisons of marker MFI and homogene-
ity with known NK population signatures, a process similar 
to manual gating of cytometry data visualized in dot plots 
(Figure 1). Accordingly, two groups of clusters expressing the 
highest levels of CD56, of NKG2A, no or low levels of CD16, a 
typical CD56bright signature, were thus named. Seven populations 
expressing medium levels of CD56 and high levels of CD16 
were identified as CD56dim. They included several groups dif-
ferentially expressing NKG2A and CD57, two markers linked 
to immaturity or maturity, respectively, and NKG2C, a NK cell 
receptor expanded during CMV infections. Four populations 
expressing low levels of CD56 or CD16 previously described 
in HIV-infected patients as dysfunctional NK populations were 
identified (15). Finally, phenotypes of NK cells usually found 
in human PBMC, including populations specifically expanded 
during HIV infection, and new phenotypes characterized by 
unexpected combinations of markers were found in patients’ 
samples using the automatic clustering and interactive merging 
approach. It should be emphasized that other analyses of the 
same data, based on the choice of higher or lower numbers of 
populations could have also been pertinent. As an example, the 
few clusters characterized by CD56brightCD16negNKG2C+ visible 
at the bottom of the tree were included in the CD56bright pool 
while other cuts of the tree could have separated this original 
combination of markers.
The Distribution of the Various Phenotypes 
of nK cells Defined groups of hiV-Primary 
infected Patients with Different Maturation 
Profiles
We next determined how these NK populations were individually 
distributed among the 30 primary HIV-infected patients. The 
blocks of clusters were imported into a spreadsheet program, 
leading to a matrix with a population name, associated with initial 
counts of events and patient number. The frequencies of the 12 
populations within the total NK cells of each patient were calculated 
and summarized using pivot tables (Table S1 in Supplementary 
Material). One population (CD56negCD16+CD57+), although 
present in different patients, represented less than 0.5% of total 
NK cells and was excluded from the analysis. Frequencies of 
the 12 remaining populations were visualized in a MeV heat-
map and used to cluster patients (Figure 2A). Three groups of 
patients, named X, Y, and Z appeared on the map. Group X was 
characterized by the highest frequencies of CD56dimNKG2A+ 
and CD56negCD16+NKG2A+ NK cells. Group Y showed high 
frequencies of CD56dimNKGC2+CD57+and CD56dimCD57+ 
NK cells. Group Z contained mainly a population of CD56dim 
CD57−NKG2A− NKG2C− (Figure 2A).
We checked whether the frequencies of the most frequent NK 
cell populations directing the clustering (the four populations 
on top of the list) were significantly different between the three 
groups (Figure 2B). Group X showed significant higher frequen-
cies of CD56dimNKG2A+ than Y and Z (34% vs., respectively, 13.8 
and 14.3%). Group Y showed significant higher frequencies of 
CD56dimCD57+ NK cells than X and Z (21% vs., respectively, 2.9 
and 7.2%), and higher frequencies of CD56dimNKG2C+CD57+ than 
X and Z (17.8% vs., respectively, 2.9 and 0.9%). Group Z showed 
42.6% of CD56dim NKG2A−NKG2C−CD57− while this phenotype 
represented only 12 or 16% of NK cells in, respectively, X and Y. 
Accordingly, the three groups of patients were significantly char-
acterized by, respectively, high proportion of CD56dimNKG2A+ 
for group X, high proportion of CD56dimCD57+ NK cells for group 
FigUre 1 | identification of natural killer (nK) cell populations. Visualization of the 756 clusters computed into the NK cells files from the 28 T0 patients’ 
samples in a MeV heatmap. The clusters are visualized and merged according to their normalized MFI for the five markers shown on top using the MeV software 
hierarchical clustering tools. NK populations are defined as groups of merged clusters and annotated according to their signatures shown on the right.
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FigUre 2 | Patients grouping according to the frequencies of groups of natural killer (nK) populations. (a) Double clustering of the 12 most frequent NK 
populations shown on right (lines) according to their percentages among NK cells of patients (columns). The squares display the respective frequencies according to 
the scale of color shown on top. (B) Patients X, Y, and Z display significant differences of percentages of CD56dim NKG2A+, CD56dim, CD56dimCD57+NKG2C+, and 
CD56dimCD57+ populations. Errors bars represent the median and the interquartile range. p-Values from Kruskall–Wallis test are indicated on top of groups, p-Values 
from Dunn’s multiple comparison posttest on top of pairs: *<0.05; **<0.01; ***<0.001.
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Y, and high proportion of CD56dim NKG2A−NKG2C−CD57− for 
group Z.
nK cell Profiles of Patients correlated 
with hiV Viral load at inclusion
To evaluate the relationship between NK profiles of patients 
and HIV infection, the clinical and virological characteristics of 
patients within groups were compared at T0 (Table 2). Primary 
infection was defined by detectable plasma HIV-RNA and incom-
plete HIV-1 western blot, acute infection by one band or fewer 
(21) and early infection by more than one band. Four out of 14 
patients from group X, 4 out of 10 patients of group Y, and all 4 
patients of group Z were acutely infected (Figure 3A). The mean 
age of patients from each group was not significantly different (37, 
40, and 42 years for, respectively, X, Y, and Z), nor was the mean 
of estimated time since infection and enrollment (36.5, 35.3, and 
34.7 days for, respectively, X, Y, and Z) (Table 2). T-CD4 counts 
were similar for all groups, although group Z patients showed a 
trend to lower levels (Table 2). T-CD8 counts were significantly 
higher in X than Y and Z (mean of 2,148 counts/μL vs. 1,308 and 
1,415 for, respectively, Y and Z) (Table 2).
A striking difference was observed when the viral load was 
compared between the three patient groups. Patients from 
groups X and Z displayed significantly higher mean HIV-RNA 
levels than patients from group Y (respectively, 5.77 log10 HIV-
RNA  copies/mL and 6.05 log10 HIV-RNA  copies/mL vs. 4.88 
log10 HIV-RNA  copies/mL in group Y), while HIV-DNA were 
not significantly different despite a trend to lower levels for Y 
(Figure 3B). Thus, the major differences observed between the 
FigUre 3 | clinical and virological characteristics of patients groups 
at T0. (a) Primary infection status of patients according to the X, Y, and Z 
groups. (B) Human immunodeficiency virus (HIV) viral load. Plasma HIV-RNA 
(left), HIV-DNA copies associated to millions of T-CD4 cells (right). Error bars 
represent the median and interquartile range. p-Values from Kruskall–Wallis 
are indicated on top of groups, p-Values from Dunn’s multiple comparison 
posttest on top of pairs: *<0.05; **<0.01; ***<0.001.
TaBle 2 | groups characteristics.
groups of patients
characteristics X Y Z
Number of patients 14 10 4
Acute (% in the group) 28 40 100
Time between estimated date of 
infection and enrollment (days)
36 (23–55) 35 (22–46) 35 (32–41)
Age (years) 37 (23–64) 40 (23–62) 42 (24–55)
CD4 counts (count/μL) 549 
(323–1,012)
584 
(368–864)
430 
(341–513)
CD8 counts (count/μL) 2,148 
(502–8,157)
1,308 
(417–2,716)
1,415 
(1,140–1,966)
CD4 to CD8 ratio 0.41 
(0.08–1.3)
0.57 
(0.23–1.1)
0.31 
(0.2–0.35)
Human immunodeficiency virus 
(HIV)-RNA (log10 cp/mL)
5.77  
(4.6–7)
4.88  
(3.2–5.7)
6.05  
(5.6–7)
HIV-DNA (log10 cp/106 peripheral 
blood mononuclear cell)
3.8  
(3.2–4.7)
3.5  
(2.8–4.3)
3.9  
(3.2–4.5)
Progenitors [% of natural killer 
(NK)]
7.7  
(3–20)
4  
(0–13.9)
6.3  
(0.9–9.5)
Effectors (% of NK) 49.2 (29–66) 20.8 (8–28) 0
Intermediate (% of NK) 17.5  
(3.5–29)
22.7 
(10–39.5)
45.7 
(40.5–56)
Mature (% of NK) 6.8 (0–16) 39 (21–54) 8.2 (2.7–15)
Dysfunctional (% of NK) 15 (5.7–41) 10.6 
(3.2–21.6)
11.7 
(2.3–16.3)
T0 mean values and (range) are indicated.
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three groups of patients at inclusion highlighted the lower viral 
load of group Y, the group defined by an expansion of CD57+ 
NK cells.
Patients with high Frequencies of Mature 
nK cells Displayed Better immunological 
Parameters at inclusion
We next addressed the question of whether patients of group X, Y, 
and Z were different with respect to other major disease progres-
sion markers. We analyzed plasma inflammatory markers (IL-6, 
IP-10) (25, 26) and also focused on markers of innate immune 
activation and exhaustion, including CD38 expression on NK 
cells, CD86 expression on monocytes, PDL-1 expression on mDC 
(27), and pDC and mDC frequencies (28). These markers were all 
described to be linked to viral load and disease progression (29). 
They were compared between the groups of patients and some of 
them were compared to a group of 15 healthy donors (Figure 4).
Patients of group X displayed higher IL-6 and IP-10 plasma 
levels than patients of group Y (Figure  4A). CD38 expression 
on NK cells was significantly increased in all patients groups as 
compared to healthy donors. CD86 on monocytes and PDL-1 on 
mDC were significantly increased in patients X as compared to 
healthy donors, while patients Y showed a trend to lower increase 
and values of PDL-1 not different from that of healthy donors 
(Figure 4B). All patients groups showed significant decrease of 
pDC as compared to healthy donors, but patients Y showed a 
clear trend to higher values of pDC frequencies (Figure 4C). Only 
patients X and Z showed significant decrease of mDC frequen-
cies while patients Y exhibited values similar to healthy donors 
(median of, respectively, 0.3 vs. 0.33%) (Figure 4C). Therefore, in 
addition to exhibit the lowest activation, Y patients displayed low 
exhaustion of DC, as shown by a trend to higher frequencies of 
pDC and frequencies of mDC not different from that of healthy 
donors (Figure 4C). As expected according to their high viremia 
levels, patients from groups X and Z displayed higher immune 
activation and exhaustion while patients Y exhibited a better 
immune status in PHI.
Patients with high Frequencies of Mature 
nK cells Displayed a lower Viral load 
after 3 Months of carT
We then assessed the impact of the different virological and 
immunological status at inclusion on early cART outcome. While 
all patients showed a 3-log decrease of viral load after 3 months of 
cART (Table 2), we searched for those patients having reached a 
viral load below 50 copies/mL at M3. Notwithstanding the cART 
regimen, 6 out of 14 (57%) patients X, 1 out of 4 (25%) patients 
FigUre 4 | immune status of patient groups at T0. (a) Plasma levels of IL-6 and of IP-10. (B) Innate immune cells activation of patients groups and a group of 
15 healthy donors. CD38 expression on natural killer cells, CD86 expression on monocytes, PDL-1 expression on mDC. (c) Dendritic cell exhaustion. Frequencies 
of pDC’s and mDC’s in the patients groups and in a group of 15 healthy donors. Errors bars represent the median and interquartile range. p-Values from Kruskall–
Wallis test are indicated on top of groups, p-Values from Dunn’s multiple comparison posttest on top of pairs: *<0.05; **<0.01; ***<0.001.
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Z, and 7 out of 10 (70%) patients Y reached a viral load below 
50 copies/mL at M3. Taken together, only 38% of patients lack-
ing significant frequencies of CD57+ NK cells (X + Z) reached a 
threshold of 50 log10 HIV-RNA copies/mL at M3 whereas 70% 
of patients with high frequencies of CD57+ NK cells (Y) could 
reach it.
early carT Modestly Modify the 
Frequencies of Mature cD57+ nK  
cells at M3
In order to evaluate the kinetics of NK cell maturation at a short 
time after infection, we compared the frequencies of CD57+ 
NK cells at inclusion and after 3 months of cART in groups of 
patients X, Y, and Z (Figure 5). All CD57+ NK cells were summed. 
HIV-RNA showed a mean decrease of 2 logs in both groups after 
1 month of treatment, one additional log being lost during the 
third month (left graph). In the meantime, the frequency of CD57 
NK cells remained unchanged in patients from group Y (47.5% at 
T0 vs. 48.9% at M3), while the frequencies of CD57 populations 
of patients from group X and Z significantly increased, or alter-
natively the proportion of immature NK cells decreased (13.9% at 
T0 vs. 20.5% at M3 for X; 11.7 vs. 19.4% for Z). Therefore, even if 
the frequencies of CD57 NK cells increased during the 3 months 
of cART, the values reached remained far from those of patients 
from group Y at T0 (47.5%).
FigUre 5 | Kinetics of viral load and of mature natural killer (nK) cells frequencies during 3 months of combination antiretroviral therapy (carT). Left 
graph shows the kinetics of human immunodeficiency virus-RNA between T0 and M3 after cART onset. Right graph shows the kinetics of the frequencies of mature 
NK cells between T0 and M3. Errors bars represent the median and interquartile range.
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DiscUssiOn
Natural killer cells are potent effectors of the innate immune sys-
tem and key actors in the race engaged between the virus and the 
host. NK cell compartment is constituted by populations more 
or less advanced on the maturation pathway, which compose a 
unique landscape at an individual level. We studied the NK cell 
compartment of HIV-infected patients at the time of primary 
infection. In spite of limitations such as the number of patients 
and the lack of samplings before infection, our results globally 
support a link between NK cell compartment skewed toward 
maturation and decreased levels of viral load and immune activa-
tion at the time of the primary HIV infection.
While multiparametric cytometry allows deep investigation of 
human immune cells, discrete subsets resulting from unexpected 
combinations of markers are found by chance using classical 
manual analysis. Computation, through the consideration of 
all parameters at the same time allowed exploration of the full 
dataset and finding discrete subsets in an unsupervised approach 
(22). The description of the NK cells of patients into 12 subsets, 
whereas only six would have been searched according to previous 
reports (CD56bright, four populations of CD56dim and CD56neg), 
provides an added value to the comprehension of the ongoing 
interplays between NK cell and HIV. One example is the finding 
of four different CD56neg subsets and their clustering near four 
different NK cell populations, including CD56bright. This result 
suggests that the defect affecting the NK cell can touch the lineage 
at different levels of maturation.
Among 12 NK populations, four co-expressed NKG2C in vari-
ous combinations spanning the whole NK maturation process. 
The clustering of the CD56dimNKG2A+NKG2C+ subset near 
CD56brightCD16low, previously described at the transition between 
CD56bright and CD56dim (30), suggests they originate from the 
progenitor. NKG2C+ NK cell expansion was reported previously 
in HIV primary infection (10, 11, 16) and described during 
Hantavirus and Chikungunya acute infections (12, 31), always in 
the context of underlying CMV co-infection. The identification 
of discrete NKG2C+ NK cells subsets with a phenotype close to 
the NK cell progenitor suggests an ongoing generation during 
primary HIV infection.
The individual distribution of those 12 NK cell populations 
permits constitution of homogeneous and significantly differ-
ent groups of patients. Group X included 14 patients whose 
NK cells were mainly composed of CD56dimNKG2A+, group Y 
included 10 patients with high frequencies of CD56dimCD57+ 
and CD56dimCD57+NKG2C+, and group Z included four 
patients whose NK cells displayed a CD56dimNKG2A−NKG
2C−CD57− phenotype. To understand the role of those dif-
ferences on HIV primary infection, clinical, virological, and 
immunological characteristics of the patients groups were 
compared. Kinetics of HIV infection could have been involved, 
but this hypothesis was not sustained by the comparison of the 
estimated time since infection or by the status of antibodies 
developed to HIV, defining an acute or early primary infection. 
The striking difference was the viral load at inclusion: patients 
with high frequencies of CD56dimCD57+ NK cells (group Y) 
had significantly lower levels of HIV-RNA than patients with 
highest frequencies of CD56dimNKG2A+ (group X) or CD56dim
NKG2A−NKG2C−CD57− NK cells (group Z). Although the low 
number of patients limits the significance of some comparisons, 
patients Y, as expected according to their lower levels of HIV-
RNA, showed lower immune activation and lower exhaustion 
of immune cells than patients X and Z. cART initiated in this 
better environment resulted in increased efficiency at M3. 
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Interestingly, one of the 10 patients showing high frequencies 
of mature NK cells at inclusion became later a PTC (21).
CD57 is a marker of senescence highly correlated to expression 
of self-KIR that identifies fully mature NK cells (4). Immature 
KIR− NK cells mostly express NKG2A to regulate their activity, 
only a small subset of NK cell co-express NKG2A and KIR. 
Accordingly, CD57+ and NKG2A+ NK cells were considered as 
covering, respectively, mature and immature NK populations. 
Accordingly, the balance of the NK cell compartment maturation 
is indeed the difference between the groups: NK cell of patients Y 
are mainly mature CD57+ cells whereas most NK cells of patients 
X are immature. Thus, the NK cell maturation profile at the time 
of primary infection appears to be a pertinent marker of a bet-
ter immune status and response to cART started at the primary 
infection.
The status of the NK cells before HIV infection is not known. 
Because NK cell maturation is a dynamic process, imbalance of 
the NK cell compartment toward maturity or immaturity could 
be a rapid early consequence of HIV infection. CD57+ NK cells 
proliferate only slightly (4). The dynamics of their generation 
proposed by the follow-up of NKG2C subset during CMV reacti-
vation in transplant patients (32) suggested that NKG2C+CD57+ 
resulted from the contraction of effector NKG2C+ several months 
after control of CMV viremia. During the 3  months of cART, 
while HIV viremia was controlled, the frequencies of CD57+ NK 
cells slightly increased in the Optiprim patients with low levels at 
inclusion but remained far below the values exhibited by patients 
with high frequencies at inclusion, suggesting that the dynamics 
of NK cell maturation is slower than that of viral load. An expan-
sion of CD56dim was reported during HIV primary infection (14). 
According to the inverse relationship between proliferation and 
maturation, this expansion should result in decreasing even more 
the frequencies of mature CD56dimCD57+. Taking into account 
the limited proliferation of mature CD56dimCD57+ and the slow 
dynamics of their generation, it is reasonable to speculate that the 
imbalance of the NK cell compartment toward maturation found 
at inclusion corresponded to its status at the time of HIV infec-
tion, whereas the imbalance toward immature NK cells might be 
a consequence of early NK cell expansion.
Accordingly, mature CD57+ NK cell already present at the time 
of HIV infection must contribute better to immune control of 
the virus than CD56dimNKG2A+ NK cells does. As demonstrated 
in the NKG2C/CMV model, memory-like NKG2C+CD57+ NK 
cells expanded after CMV reactivation are potent producers of 
IFN-γ (8). Accumulation of NK cells expressing self-KIR was 
demonstrated in HIV PTCs of the Visconti study (33). Those 
NK cells were potent producers of IFN-γ upon stimulation with 
HIV-infected targets, suggesting that this function was crucial 
for virus control. IFN-γ can induce maturation and activation 
of T cells, DC, and macrophages (3), which cooperate in virus 
control. Indeed, DC frequencies in patients with high frequencies 
of mature CD57+ NK cells were similar to healthy donors, sug-
gesting indeed that innate immunity overall was involved.
Paradoxically, a prospective study on a cohort of prostitutes 
demonstrated an increased risk of HIV infection among those 
displaying highly diverse NK cell repertoire before infection, 
diversity being intrinsically linked to maturation (20). The high 
efficiency of NKG2A+ NK cell to kill HIV-infected CD4-T cell 
targets in  vitro, recently demonstrated (34) is an underlying 
mechanism that could be involved in the decreased susceptibility 
to HIV infection of prostitutes displaying an immature NK cell 
compartment before infection. Taken together, these observa-
tions suggest that if immature NK cells are efficient at the time of 
infection, once infection is established, other mechanisms involv-
ing mature CD57+ NK cells contribute better to virus control.
Natural killer cell diversity increases with aging and the 
number of stimulations encountered, resulting in accumulation 
of mature NK cells heterogeneous with respects to functional 
activating and inhibitory receptors (20). Groups of patients 
showed similar mean age, their NK cell profiles should rather 
be attributed to individual histories resulting in a unique shap-
ing of their NK cell repertoire. NKG2C+CD57+ NK cell could 
be considered as a particular subset of the mature CD57+ NK 
cell compartment whose ligand is known. Increased expression 
of HLA-E on HIV-infected cells suggest a possible mechanism 
involving NKG2C+ NK cells (35). Other subsets of the mature 
CD57+ pool might share unknown receptor specificities diversely 
able to target HIV-infected cells. Besides their functional recep-
tors characteristics, NKG2C+CD57+ NK cells expanded after 
CMV infection are now considered as a memory-like or adaptive 
form of NK cells (8, 13). Recently, this subset has been character-
ized by a low expression of FcRγ (36) and enhanced potential 
for broad antiviral responses in the presence of virus-specific 
antibodies (37). While we cannot identify unambiguously adap-
tive NK cells, the CD57+ NK cells found in patients partially 
controlling their viral load certainly overlap them. Irrespective 
of the various mechanisms possibly underlying the contribution 
of mature NK cell to HIV control, once infection is established, 
evaluation of this parameter during the primary HIV infection 
appears relevant in the search for prognostic markers to monitor 
HIV-infected patients.
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